X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (920) 920
life sciences & biomedicine (903) 903
sglt2 inhibitor (624) 624
type 2 diabetes (600) 600
diabetes (599) 599
humans (582) 582
diabetes mellitus, type 2 - drug therapy (441) 441
glucose (434) 434
endocrinology & metabolism (406) 406
sglt2 inhibitors (391) 391
male (329) 329
diabetes mellitus (306) 306
hypoglycemic agents - therapeutic use (290) 290
sglt2 (277) 277
dapagliflozin (275) 275
female (263) 263
sodium-glucose transporter 2 - antagonists & inhibitors (263) 263
dextrose (254) 254
pharmacology & pharmacy (244) 244
middle aged (227) 227
type 2 diabetes mellitus (207) 207
glucosides - therapeutic use (201) 201
animals (187) 187
canagliflozin (176) 176
empagliflozin (175) 175
hypoglycemic agents - adverse effects (166) 166
treatment outcome (164) 164
sodium (162) 162
aged (158) 158
insulin (151) 151
heart failure (150) 150
adult (144) 144
analysis (144) 144
clinical trials (140) 140
blood pressure (139) 139
benzhydryl compounds - therapeutic use (134) 134
diabetes mellitus, type 2 - blood (133) 133
care and treatment (131) 131
sodium-glucose transporter 2 - metabolism (131) 131
hypoglycemic agents - pharmacology (130) 130
metformin (130) 130
glucosides - adverse effects (126) 126
internal medicine (126) 126
drug therapy (124) 124
blood glucose - drug effects (122) 122
diabetes therapy (122) 122
hypoglycemic agents (120) 120
medicine & public health (116) 116
hypoglycemic agents - administration & dosage (114) 114
body weight (111) 111
glucosides - pharmacology (111) 111
hyperglycemia (110) 110
blood glucose - metabolism (108) 108
double-blind method (108) 108
review (102) 102
cardiovascular system & cardiology (101) 101
glucosides - administration & dosage (100) 100
diabetes mellitus, type 2 - complications (98) 98
cardiovascular disease (94) 94
diabetes mellitus, type 2 - metabolism (93) 93
risk factors (91) 91
cardiac & cardiovascular systems (89) 89
endocrinology (89) 89
drug therapy, combination (88) 88
hypoglycemia (88) 88
glucose metabolism (86) 86
general & internal medicine (84) 84
benzhydryl compounds - adverse effects (82) 82
medicine, general & internal (80) 80
cardiology (77) 77
dose-response relationship, drug (77) 77
glucose transporter (76) 76
patients (76) 76
glycosylated hemoglobin (74) 74
original (74) 74
benzhydryl compounds - pharmacology (73) 73
insulin resistance (72) 72
diabetes mellitus, type 2 - physiopathology (70) 70
inhibitors (69) 69
sodium-glucose transporter 2 inhibitors - therapeutic use (67) 67
blood pressure - drug effects (66) 66
hemoglobin (66) 66
hypertension (66) 66
mortality (66) 66
young adult (64) 64
benzhydryl compounds - administration & dosage (62) 62
medical research (62) 62
cardiovascular diseases (61) 61
original article (61) 61
glucosides - pharmacokinetics (60) 60
kidneys (60) 60
research (60) 60
glucose - metabolism (59) 59
glycated hemoglobin a - metabolism (59) 59
kidney - drug effects (58) 58
meta-analysis (58) 58
kidney - metabolism (57) 57
metabolism (57) 57
canagliflozin - therapeutic use (56) 56
kidney diseases (56) 56
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1421) 1421
Chinese (28) 28
French (23) 23
Japanese (21) 21
German (15) 15
Spanish (10) 10
Russian (9) 9
Czech (8) 8
Korean (4) 4
Slovak (4) 4
Polish (2) 2
Arabic (1) 1
Italian (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, obesity & metabolism, ISSN 1463-1326, 06/2018, Volume 20, Issue 11, pp. 2585 - 2597
Aims Sodium glucose co‐transporter 2 inhibitors (SGLT2i) are indicated for treatment of type 2 diabetes mellitus (T2DM... 
SGLT2 inhibitor | type 2 diabetes | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Humans | Middle Aged | Observational Studies as Topic - statistics & numerical data | Hospitalization - statistics & numerical data | Male | Diabetes Mellitus, Type 2 - epidemiology | Heart Failure - prevention & control | Young Adult | Canagliflozin - therapeutic use | Aged, 80 and over | Adult | Female | Databases as Topic - statistics & numerical data | Retrospective Studies | Diabetic Angiopathies - prevention & control | Heart Failure - epidemiology | Heart Failure - etiology | Diabetes Mellitus, Type 2 - complications | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Diabetic Foot - prevention & control | Risk Factors | Diabetic Foot - surgery | Diabetic Foot - etiology | Treatment Outcome | Diabetic Angiopathies - therapy | Diabetic Foot - epidemiology | Adolescent | Diabetic Angiopathies - epidemiology | Aged | Amputation - statistics & numerical data | Diabetes Mellitus, Type 2 - drug therapy | Heart failure | Type 2 diabetes | Medical research | Databases | Amputation | Medicine, Experimental | Comparative analysis | Risk factors | Knee | Glucose transporter | Diabetes mellitus | Clinical trials | Cardiovascular disease | Patients | Meta-analysis | Sodium | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Original
Journal Article
Nephrology, dialysis, transplantation, ISSN 1460-2385, 11/2018, Volume 33, Issue 11, pp. 2005 - 2011
Background. The sodium-glucose co-transporter 2 inhibitor dapagliflozin decreases haemoglobin A1c (HbA1c... 
LONG-TERM | METFORMIN | SGLT2 INHIBITORS | dapagliflozin | 28-WEEK EXTENSION | 24-WEEK | MELLITUS | SGLT2 inhibitor | INADEQUATE GLYCEMIC CONTROL | kidney | type 2 diabetes | DOUBLE-BLIND | CARDIOVASCULAR-DISEASE | PLACEBO-CONTROLLED TRIAL | diabetic nephropathy
Journal Article
Journal of gastroenterology, ISSN 1435-5922, 03/2016, Volume 51, Issue 12, pp. 1141 - 1149
Journal Article
Journal Article
Cardiovascular diabetology, ISSN 1475-2840, 02/2019, Volume 18, Issue 1, pp. 20 - 20
Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D... 
Cardiac & Cardiovascular Systems | Endocrinology & Metabolism | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Sodium-Glucose Transporter 1 - antagonists & inhibitors | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 - drug effects | Kidney - drug effects | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Sodium-Glucose Transporter 2 - metabolism | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Treatment Outcome | Biomarkers - blood | Diabetes Mellitus, Type 1 - drug therapy | Blood Glucose - drug effects | Diabetes Mellitus, Type 1 - diagnosis | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - blood | Kidney - metabolism | Animals | Diabetes Mellitus, Type 1 - blood | Glycosides - adverse effects | Sodium-Glucose Transporter 1 - metabolism | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Glycosides - therapeutic use | Glucose transporter | Urine | Medical research | Excretion | Kidneys | Peptides | Diabetes mellitus | Clinical trials | Systematic review | Diabetes mellitus (insulin dependent) | Glucose | Insulin | Small intestine | Optimization | Infusion | Inhibitors | Sodium | Intestine | Hemoglobin | Blood pressure | Adults | Diabetes | Diabetes mellitus (non-insulin dependent) | Transporter | Index Medicus | Hypoglycemic therapy | SGLT2 inhibitors
Journal Article